Indian Nexavar case hearing complete; order reserved
This article was originally published in Scrip
Executive Summary
The hearing on the crucial Indian case concerning Bayer's appeal against the compulsory licence granted for its anticancer Nexavar (sorafenib tosylate) to the domestic firm, Natco Pharma, has been completed.